| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
IDR-1 does not directly target pathogens but instead modulates host immune responses. It selectively modulates innate immunity to counter infections while avoiding evident toxicities. The peptide enhances protective innate immunity by promoting chemokine production, immune cell recruitment, and balanced inflammatory responses.
|
|---|---|
| ln Vitro |
In vitro, IDR-1 enhances monocyte chemoattractant levels and attenuates the release of pro-inflammatory cytokines. It has anti-inflammatory and anti-infective properties. The peptide modulates immune cell function and promotes a balanced inflammatory response rather than directly killing bacteria.
|
| ln Vivo |
In vivo, IDR-1 fights infection by selectively modulating innate immunity without apparent toxicity. It is active against both Gram-positive and Gram-negative bacteria in animal models. The peptide's immunomodulatory activity makes it a promising candidate for treating infectious diseases.
|
| Enzyme Assay |
Receptor/enzyme binding studies for IDR-1 typically involve assessing its interaction with immune cells rather than direct receptor binding. Flow cytometry and ELISA are used to measure chemokine production and cytokine release in response to the peptide.
|
| Cell Assay |
Cell-based assays for IDR-1 utilize immune cells such as monocytes or macrophages. Cells are treated with the peptide, and chemokine and cytokine levels in the culture medium are measured by ELISA. Immune cell recruitment and activation are assessed by flow cytometry.
|
| Animal Protocol |
In vivo studies with IDR-1 are conducted in rodent models of infection. The peptide is typically administered via intraperitoneal or subcutaneous injection. Bacterial load, immune cell infiltration, and inflammatory markers are assessed in infected tissues.
|
| ADME/Pharmacokinetics |
As a 13-amino-acid peptide, IDR-1 is expected to have a short half-life due to proteolytic degradation. The peptide should be stored as a lyophilized powder at -20degC. Standard peptide handling and storage procedures apply.
|
| Toxicity/Toxicokinetics |
Toxicity data for IDR-1 indicate that it fights infection without apparent toxicity. The peptide is generally considered to have low toxicity at pharmacological doses. Standard safety precautions for laboratory handling of peptides should be followed.
|
| References | |
| Additional Infomation |
IDR-1 is a research-use peptide and is not approved for therapeutic applications. It is a synthetic peptide designed to modulate host immune responses. The peptide is used to study innate immunity, host defense peptides, and the development of immunomodulatory therapies. It is available from multiple research suppliers.
|
| Molecular Formula |
C12H22N2O3
|
|---|---|
| Molecular Weight |
242.314683437347
|
| Exact Mass |
242.163
|
| CAS # |
940291-10-1
|
| PubChem CID |
71433923
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.141
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
17
|
| Complexity |
242
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CCC.C[C@@H](C=O)NC(=O)[C@@H]1CCCN1C=O
|
| InChi Key |
RCTYDUUDOSRQTI-WSZWBAFRSA-N
|
| InChi Code |
InChI=1S/C9H14N2O3.C3H8/c1-7(5-12)10-9(14)8-3-2-4-11(8)6-13;1-3-2/h5-8H,2-4H2,1H3,(H,10,14);3H2,1-2H3/t7-,8-;/m0./s1
|
| Chemical Name |
(2S)-1-formyl-N-[(2S)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide;propane
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1269 mL | 20.6347 mL | 41.2694 mL | |
| 5 mM | 0.8254 mL | 4.1269 mL | 8.2539 mL | |
| 10 mM | 0.4127 mL | 2.0635 mL | 4.1269 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
